Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Zach Ehlinger Clear advanced filters

  • Combination of TCR or CAR T cells expressing the engineered CD47 variant 47E with anti-CD47 antibody therapy results in synergistic antitumour efficacy due to T cell resistance to clearance by macrophages, while maintaining macrophage recruitment into the tumour microenvironment.

    • Sean A. Yamada-Hunter
    • Johanna Theruvath
    • Crystal L. Mackall
    ResearchOpen Access
    Nature
    Volume: 630, P: 457-465

  • Single-cell proteomic profiling of circulating CAR T cells in patients treated with CD19-CAR shows that CD4+Helios+ CAR T cells on day 7 after infusion are associated with progressive disease and less severe neurotoxicity.

    • Zinaida Good
    • Jay Y. Spiegel
    • Crystal L. Mackall
    Research
    Nature Medicine
    Volume: 28, P: 1860-1871

  • A phase I dose-escalation trial of GD2-CAR T cells in children and young adults with diffuse midline gliomas to assess the feasibility of manufacturing, safety and tolerability, and to preliminarily assess efficacy.

    • Robbie G. Majzner
    • Sneha Ramakrishna
    • Michelle Monje
    ResearchOpen Access
    Nature
    Volume: 603, P: 934-941